The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
European Journal of Clinical Investigation2015Vol. 45(6), pp. 609–623
Citations Over TimeTop 10% of 2015 papers
Abstract
Ras/MAPK pathway effectors may be considered as potential therapeutic targets in the field of HCC. In particular after the arrival of sorafenib, more Ras/MAPK inhibitors have emerged and are still in preclinical or clinical investigation for HCC therapy.
Related Papers
- → Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma(2017)36 cited
- → CircPHKB decreases the sensitivity of liver cancer cells to sorafenib via miR-1234-3p/CYP2W1 axis(2023)5 cited
- → Combination treatment with sorafenib and wh‑4 additively suppresses the proliferation of liver cancer cells(2022)5 cited
- → Sorafenib regulating ERK signals pathway in gastric cancer cell(2014)2 cited
- Research Progress on Sorafenib Combined with Intervention in the Treatment for Advanced Hepatocellular Carcinoma(2015)